Adcytherix gains $122m to propel ADC development
Adcytherix has set a target to file for an IND and clinical trial applications in Canada, the UK, and the EU by the end of 2025.
Drug Development
Tubulis closes $361m in Series C to advance cancer treatment
Nabla Bio expands Takeda collab for protein therapeutics
BioCryst to buy Astria Therapeutics for $700m in enterprise value
CIPO grants patent to Palisade Bio’s PALI-2108
J&J in talks to acquire Protagonist Therapeutics
FDA approves Teva and Medincell’s bipolar I disorder treatment
FDA ‘green list’ flagging illegal GLP-1RA compounders is long overdue
